Further information

Abberrant RNA-protein interactions in late-onset diseases

12968 1518711595

Talk by Dr. Sybille Krauß, DZNE Bonn

  • Date: Mar 5, 2018
  • Time: 14:00 - 15:00
  • Speaker: Dr. Sybille Krauß
  • Research Group Leader, Group 'Regulatory RNA-protein interactions in neurodegenerative diseases', Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), Bonn
  • Location: MPI for Metabolism Research, Gleueler Strasse 50, 50931 Köln
  • Room: Seminar room 1
  • Host: Dr. Thomas Wunderlich
  • Contact: thomas.wunderlich@sf.mpg.de
Late onset diseases such as cancer and neurodegenerative diseases represent an enormous burden in our ageing population. An in depth understanding of molecular pathomechanisms is a prerequisite for the development of novel treatment strategies. Our major research interest is in regulatory RNA-protein interactions, an important and often overlooked cellular phenomenon that plays an essential role in disease-development. RNA-function depends on the 3-dimensional structure of the RNA as well as on interaction with RNA-binding proteins. The main goal of our research is to identify and characterize regulatory RNA-protein interactions in healthy and disease tissue, especially in late onset diseases such as cancer and neurodegenerative diseases.In my group, we have identified an RNA-protein complex containing the ubiquitin ligase MID1 that plays an important role in regulating protein synthesis and that is significantly upregulated in late onset diseases including Huntington’s disease, Alzheimer’s disease or certain types of cancer. This aberrant MID1-activity leads to an increased protein production of proteins that are causal for disease-development.Thus, our data suggest that MID1 is a key regulator in disease development. Furthermore, our preliminary results indicate that MID1 localizes to cytosolic RNA granules and interacts with proteins involved in RNA granule assembly, RNA transport and local protein synthesis. In our ongoing experiments we further investigate the exact molecular function of MID1 and its interactome, especially focusing on the molecular pathways that are triggered by MID1 over-expression in disease tissue. Interestingly, these pathways include mTOR-signaling and insulin / insulin-like growth factor-1 (IGF-1) signaling pathways.
 
Go to Editor View
loading content